Medivation Battles UCLA Over Rights To Prostate Cancer Compound
Executive Summary
UCLA researchers secretly developed a compound almost identical to Medivation’s MDV3100 (enzalutamide), a breach of contract suit claims. The company expects to launch MDV3100 later this year.
You may also be interested in...
With New Data For A Drug In Dispute, Aragon Raises $50 Million
The San Diego biotech’s Series D round will support continued development of a drug that Medivation claims was included in the same license that covered the recently approved prostate cancer drug Xtandi.
More Competition In Prostate Cancer? Medivation’s Enzalutamide Now With FDA
Medivation and Astellas have submitted their castration-resistant prostate cancer drug enzalutamide to FDA and hope to gain priority review for the long-anticipated therapy.
Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial
A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.